DAB2IP predicts treatment response and prognosis of ESCC patients and modulates its radiosensitivity through enhancing IR-induced activation of the ASK1-JNK pathway

Yue Li

First Affiliated Hospital of Anhui Medical University

Meng Xu

First Affiliated Hospital of Anhui Medical University

Weiyang Fang

First Affiliated Hospital of Anhui Medical University

Lei Sheng

First Affiliated Hospital of Anhui Medical University

Xiangcun Chen

First Affiliated Hospital of Anhui Medical University

Jifei Xu

First Affiliated Hospital of Anhui Medical University

Tianqi Zha

First Affiliated Hospital of Anhui Medical University

Liang Xiao

First Affiliated Hospital of Anhui Medical University

Shuhao Pan

First Affiliated Hospital of Anhui Medical University

Huaguang Pan

First Affiliated Hospital of Anhui Medical University

Huiping Chai

First Affiliated Hospital of Anhui Medical University

Lei Zhao

Sun Yat-sen University Cancer Center

Hao Wang

First Affiliated Hospital of Anhui Medical University

Dan Xie

Sun Yat-sen University Cancer Center

Zhuting Tong (✉ zhuting_tong@ahmu.edu.cn)

First Affiliated Hospital of Anhui Medical University

Research

Keywords: Esophageal squamous cell carcinoma, DAB2IP, chemoradiosensitivity, ASK1, JNK

Posted Date: September 18th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-23979/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

BACKGROUND: Disabled homolog 2 interacting protein (DAB2IP) plays a tumor-suppressive role in several types of human cancers. However, the molecular status and function of the DAB2IP gene in esophageal squamous cell carcinoma (ESCC) is rarely reported.

METHODS: We examined the expression dynamics of DAB2IP by immunohistochemistry (IHC) in 140 ESCC patients treated with definite chemoradiotherapy. A series of in vivo and in vitro experiments were performed to elucidate the effect of DAB2IP on the chemoradiotherapy (CRT) response and its underlying mechanisms in ESCC.

RESULTS: Decreased expression of DAB2IP in ESCCs correlated positively with ESCC resistance to CRT and was a strong and independent predictor for short disease-specific survival (DSS) of ESCC patients. Furthermore, the therapeutic sensitivity of CRT was substantially increased by ectopic overexpression of DAB2IP in ESCC cells. In addition, knockdown of DAB2IP dramatically enhanced resistance to CRT in ESCC. Finally, we demonstrated that DAB2IP regulates ESCC cell radiosensitivity through enhancing ionizing radiation (IR)-induced activation of the ASK1-JNK signaling pathway.

CONCLUSIONS: Our data highlight the molecular etiology and clinical significance of DAB2IP in ESCC, which may represent a new therapeutic strategy to improve therapy and survival for ESCC patients.

Introduction

Esophageal carcinoma is the eighth most common cancer and the sixth leading cause of cancer-related deaths worldwide. Esophageal squamous cell carcinoma (ESCC) is the dominant histological type of esophageal cancer in China, with a five-year overall survival less than 30%[1]. At present, a definitive concurrent chemoradiotherapy (CRT) has been established as the standard treatment for advanced localized ESCC[2]. However, therapeutic outcomes are not satisfactory, even with the recent rapid development of diagnostics and therapies. Chemoradioresistance is one of the most important factors for the poor prognosis in ESCC patients[3]. Currently, the molecular mechanisms underlying chemoradioresistance in ESCC have not been clearly elucidated. Thus, it is necessary to identify novel markers that can predict responses to chemoradiotherapy, so as to find novel therapeutic targets and develop new modalities of treatment.

DAB2IP, also named ASK1-interacting protein-1 (AIP1), is a novel member of the Ras-GTPase-activating protein family[4]. *DAB2IP* has been identified as an EZH2 target gene by epigenetic silencing mechanism. The N-terminal domain of DAB2IP interacts with tumor suppressor DOC2/DAB2 to form a unique protein complex that has negative regulatory activity targeting the Ras-mediated signaling pathway[5]. Recently, there has been increasing evidence that reduced expression of DAB2IP occurs in several types of human malignancies, including prostate cancer[6], lung cancer[7], hepatocellular carcinoma[8], renal cancer[9], and breast cancer[10]. Loss expression of DAB2IP was observed to correlate closely with tumor aggressiveness and/or poor patient prognosis. Several recent studies showed that downregulation of

DAB2IP expression in prostate cancer cells results in resistance to radiotherapy[6,11,12]. To date, however, the molecular status of the DAB2IP gene in ESCC and the relationship between the expression of DAB2IP and chemoradiosensitivity in ESCC has not been elucidated.

Notably, our group's previous work demonstrated that EZH2, an upstream inhibitory regulatory protein of DAB2IP, serves as a promising diagnostic biomarker for hepatocellular carcinoma[13] and supports nasopharyngeal carcinoma cell aggressiveness[14]. Most importantly, we further revealed that high expression of EZH2 was correlated with a poor response to chemoradiotherapy in ESCC patients[15]. These evidences promote us to feel great interest in determining the significance of DAB2IP, as an identified repressive target gene of EZH2, in CRT sensitivity and its effect on the prognosis of ESCC patients treated with definite CRT.

In this study, to determine whether abnormalities of DAB2IP were involved in the pathogenesis and chemoradiosensitivity of ESCC, we applied immunohistochemistry (IHC) analysis to examine the expression of DAB2IP in a cohort of biopsy specimens of primary ESCC patients treated with definitive CRT. Furthermore, to examine whether the expression of DAB2IP could predict the ESCC response to CRT and patient clinical outcomes, we evaluated the correlation between DAB2IP expression and patient clinical/prognostic factors. In addition, the underlying molecular mechanisms of DAB2IP involved in chemo/radioresistance in ESCC were investigated.

Methods

Cell culture, antibodies, and chemical reagents

The three ESCC cell lines (i.e., TE1, EC109, and Kyse150) were purchased in 2015 from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) where they were characterized by mycoplasma detection, DNA-Fingerprinting, isozyme detection and cell vitality detection. The ESCC cell line Kyse30 was kindly provided by Prof. Xiaofeng Zhu (Sun Yat-Sen University Cancer Center) in 2014. All cell lines were maintained in RPMI-1640 supplemented with 10% fetal bovine serum and were authenticated three months before the beginning of the study (2015) based on viability, recovery, growth and morphology by the supplier. All the cell lines have not been in culture for greater than 2 months.

Primary antibodies used in this study: rabbit anti-DAB2IP (ab87811, Abcam, UK); rabbit anti-cleaved poly (ADP-ribose) polymerase (PARP, Asp214), rabbit anti-cleaved caspase-3 (Asp175), mouse anti-Phospho-Histone H2AX(γ -H2AX) (Ser139), rabbit anti-53BP1, rabbit anti-AKT and anti-Phospho-AKT(Ser473), rabbit anti-JNK and anti-Phospho-JNK, rabbit anti-ERK1/2 and anti-Phospho-ERK1/2, rabbit anti-ASK1 and anti-Phospho-ASK1 (ser966), rabbit anti-14-3-3, rabbit anti-Thioredoxin(Cell Signaling Technology, Boston, MA); α -tubulin (BD Transduction Laboratories). Secondary antibodies: Dylight 549-conjugated goat anti-rabbit IgG (Proteintech Group, Inc., Chicago, IL), Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA). Peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA). Annexin V-FITC/PI apoptosis detection kit (Vazyme Biotech, China).

Ethics approval and consent to participate

All patients authorized the use of their specimens by written informed consent. This study was approved by the Institute Research Medical Ethics Committee of Anhui Medical University (Hefei, China). This study was performed in accordance with the Declaration of Helsinki.

Western Blotting

Equal amounts of whole tissue or cell lysates were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred on a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA) followed by incubating with primary antibodies against DAB2IP, cleaved-PARP, cleaved-caspase3, AKT, p-AKT, JNK, p-JNK, p-ERK1/2, and ERK1/2, Phospho-ASK1(ser966), ASK1, 14-3-3, Trx, and α -tubulin, respectively. The immunoreactive proteins were detected with enhanced chemiluminescence detection reagents (Thermo Pierce, Cramlington, UK) according to the manufacturer's instructions. Bicinchoninic acid (BCA) assay was performed to determine protein concentrations.

Additional methods

All further methods can be found in Supplementary Materials and Methods section.

Results

Patient characteristics

The clinicopathological characteristics of the 140 ESCC patients are summarized in Table S1. According to the 8th edition of the TNM classification of the American Joint Committee on Cancer (AJCC)[16], 74 patients were classified into Stage II and Stage III, and 66 cases were Stage IV. All the patients received the same regimen of concurrent CRT described above. During the study period, CR and non-CR were achieved in 36 and 104 patients, respectively. The CR rate was 25.7%. Among the 104 patients who did not achieve CR, 72 cases received adjuvant chemotherapy, and 10 cases received surgical esophagectomy. The other patients did not receive any antitumor treatments until tumor progression.

Selection of cutoff score for high expression of DAB2IP

To assess statistical significance and avoid the problems of multiple cut-point selection, X-tile program[17] was used to determine an optimal cutoff value for expression of DAB2IP protein while correcting for the use of minimum P statistics by Miller–Siegmund *P*-value correction. The calculated staining score of immunopositive cells ranged from 0 to 12 in all tissues. Based on the cut-point value determined by X-tile software related to survival status, we categorized the samples into low (IHC score ≤ 5) and high (IHC score > 5) expression subgroups (Figure1C-a,b).

Reduced expression of DAB2IP protein in ESCC cell lines and ESCC biopsy tissues

In this study, the protein levels of DAB2IP were examined by Western blotting (Figure1A). All the four ESCC cell lines expressed relatively lower levels of DAB2IP than non-cancerous esophageal control tissues. In addition, EC109 cells displayed the highest levels of endogenous DAB2IP expression, whereas Kyse150 cell line showed the lowest level expression (Figure1A, left panel). In 14 paired primary tissues, 10/14 (71.4%) showed downregulated DAB2IP expression when compared with adjacent non-neoplastic esophageal tissues. The 10 representative ESCC cases with downregulated expression of DAB2IP are illustrated in Figure1A, right panels.

Next, we performed IHC to evaluate the expression of DAB2IP in the 140 ESCC biopsy specimens and 25 corresponding normal mucosal tissues. The DAB2IP staining showed weak and diffuse immunostaining in background stromal cells. Positive signals of DAB2IP protein were predominantly located in the cytoplasm of esophageal cell and also weakly stained in the nucleus. According to the criteria mentioned above, low expression of DAB2IP was observed in 105/140(75.0%) of primary ESCCs biopsy tissues compared with only 2/25 (8%) in normal esophageal mucosa (Table S1).

Correlation of DAB2IP expression with clinicopathologic variables

Table S1 summarizes the detailed information about the rates of low expression of DAB2IP with respect to several standard clinicopathological features in the cohort. Results showed that no significant association was found between low DAB2IP expression and some of the clinicopathological features, such as patient's age, gender, and tumor location($P>0.05$). Interestingly, DAB2IP expression correlated closely with World Health Organization (WHO) grade ($P<0.001$), Tumor size ($P<0.001$), T status ($P=0.003$), Node (N) status ($P<0.001$), and distant lymph node metastasis (M) status ($P=0.017$) (Table S1).

Relationship between DAB2IP expression and CRT response

Primary CR was achieved in 25.7% (36/140) of the patients with ESCC. Moreover, using the optimal cutoff value of >5 score, DAB2IP expression was also the factor that showed a significant correlation with CRT response in the cohort ($r_p=0.322$, $n=140$, $P<0.001$) in which low expression of DAB2IP was observed more frequently in the non-CR subset than the CR subset.

Correlation between clinicopathological variables, DAB2IP expression and ESCC patient survival

Of the 140 patients with ESCC, 8 patients were lost to follow-up. The median survival time was 17.8 months. The 2-year OS and DSS for the entire cohort of patients were 38.6% and 36.6%, respectively. Kaplan-Meier analysis revealed that low-level expression of DAB2IP was associated with short overall survival time ($P=0.002$) and disease specific survival time ($P<0.001$) (Figure1C-c, d).

In log-rank test, low DAB2IP expression was also found to correlate closely with poor DSS of ESCC patients (median 14.77 versus 34.50 months, $P<0.001$) (Table S2). Further univariate Cox regression analysis identified WHO grade, tumor size, T status, N status, M status, CRT response and DAB2IP expression to have a significant impact on DSS ($P=0.012$, 0.003 , 0.001 , 0.030 , 0.022 , <0.001 and <0.001

respectively; Table S3). Other clinicopathological variables, including age, gender and location showed no significant correlation with DSS ($P=0.908$, 0.317 and 0.387 respectively; Table S3). The parameters that were significant in univariate analysis were further evaluated in Cox regression multivariate analysis. The results showed that the expression of DAB2IP ($P<0.001$), T status ($P<0.001$), and CRT response ($P=0.004$) were independent predictors of tumor prognosis (Table S4).

DAB2IP regulates the chemosensitivity of ESCC cells to cisplatin *in vitro*

To further investigate whether DAB2IP is capable of modulating the chemoresistance of ESCC cells *in vitro*, the Kyse150 cell line, which showed the lowest endogenous expression levels of DAB2IP, was subsequently transfected with pcDNA3.1-DAB2IP or the control plasmid pcDNA3.1. As shown in Figure 2A left, ectopic expression of DAB2IP in Kyse150 cells (Figure 2C, left) resulted in a substantial reduction of IC_{50} value under cisplatin treatment compared to that of the empty vector control cells ($5.52\mu M$ vs $10.97\mu M$). Consistently, stably silencing DAB2IP by lentivirus in EC109 cells, which showed a relative high expression of DAB2IP (Figure 1A, left panel), resulted in increased IC_{50} value compared with the control EC109-shluc cells ($1.35\mu M$ vs $2.78\mu M$, Figure 2A right). The knockdown efficiency of shRNA lentivirus was validated by Western blot (Figure 2C, right).

To further identify the crucial role of DAB2IP in ESCCs chemoresistance, the Annexin V/PI assay was performed to evaluate the effect of DAB2IP on apoptosis. As illustrated in Figure 2, the proportion of apoptosis was dramatically increased when Kyse150-DAB2IP cells were pretreated with cisplatin ($25.560\pm 4.680\%$ vs $38.160\pm 5.620\%$, $P=0.041$, Figure 2B, upper panels). Accordingly, ablation of endogenous DAB2IP remarkably reduced cisplatin-induced apoptosis in EC109 cells ($32.840\pm 4.57\%$ vs $21.280\pm 4.890\%$, $p=0.0403$, Figure 2B, lower panels).

In agreement with the results obtained by Annexin V/PI assay, our following Western blot analysis indicated that the ectopic expression of DAB2IP in Kyse150 cells obviously increased protein levels of cleaved-caspase 3 and cleaved-PARP induced by cisplatin (Figure 2C left). On the other hand, the depletion of endogenous DAB2IP in EC109 cells led to a substantial reduction of cleaved-caspase 3 and cleaved-PARP in the presence of cisplatin (Figure 2C right). Taken together, these results provide strong evidence that DAB2IP plays a crucial role in regulating chemosensitivity of ESCC cells.

DAB2IP influences the sensitivity of ESCC cells to ionizing radiation (IR) *in vitro*

Since our above ESCC cohort data revealed that DAB2IP expression was significantly correlated with CRT response (Table S1), we next used clonogenic assay to determine the important role of DAB2IP in ESCC radiosensitivity *in vitro*. As shown in Figure 3A, ectopic overexpression of DAB2IP in Kyse150 cells resulted in an obviously reduction of clonogenic survival fractions when compared with the corresponding control Kyse150-vector cells (Figure 3A left). In addition, increment of clonogenic survival fractions was observed in DAB2IP repressed EC109 cells in comparison to control EC109-shluc cells. Additional non-linear curve-fitting analysis of the dose-response survival curves was performed according to the linear quadratic (LQ) model, and the parameters for each curve including α value, β

value, α/β value, SF2, and sensitizing enhancement ratio (SER) were listed (Table S5). According to these values, SF2 was markedly reduced in Kyse150-DAB2IP cells compared to the control Kyse150-vector cells (0.43 vs 0.66) with consequence that SER value was 1.52. Consistently, a substantial increase of SF2 value was observed in DAB2IP-silenced EC109 cells when compared with control EC109-shluc cells (0.67 vs 0.59), which indicated that the SER of DAB2IP silencing in EC109 cells was 0.87 (Table S5).

Next, to obtain more evidence regarding the involvement of DAB2IP protein in regulating ESCC cell radiosensitivity, Annexin V/PI assay and immunoblots for detecting the apoptosis-related marker proteins (i.e., cleaved caspase-3 and cleaved PARP) was performed. As shown in Figure 3B and 3C, with the absence of IR, neither overexpression nor knockdown of DAB2IP could influence the proportion of apoptosis and the levels of apoptosis-related marker proteins. This phenomenon had changed after treating cells with 3Gy X-rays. In the presence of IR, both Annexin V/PI assay and Western blot results indicated that the apoptotic activity of DAB2IP was significantly enhanced in DAB2IP-overexpressed Kyse150 cells in contrast to control Kyse150-vector cells, whereas repression DAB2IP in EC109 cells cause a remarkable decrease of apoptotic cells ($32.360 \pm 5.210\%$ vs $17.890 \pm 4.65\%$, $P=0.023$), cleaved caspase-3, and cleaved PARP when compared with corresponding control EC109-shLuc cells.

The radiosensitizing activity of DAB2IP is associated with enhanced double-stranded DNA breaks (DSB) repair in ESCC cells

It is well known that the DSB repair capacity is closely correlated with intrinsic radiosensitivity of cells [18]. DSB repair involves the rapid phosphorylation of γ H2AX and the P53 binding protein (53BP1) recruitment in site-specific DNA damage [19]. Thus, the formation of γ -H2AX and 53BP1 foci, which displayed as discrete foci at surrounding DNA double-strand breaks, is widely used to monitor radiation-induced DNA breaks and to assay DNA rejoining defects [20].

To investigate whether DAB2IP can influence DNA repair ability of ESCC cells, the dual immunofluorescence staining for 53BP1 (red) and phospho- γ H2AX (green) foci was performed. The DSB repair kinetics was determined by counting the colocalized foci (yellow). As illustrated in Figure 3D upper panels, after 36h of IR treatment, the unrepaired DNA damage detected by counting colocalized foci of γ H2AX and 53BP1 was significantly increased in Kyse150-DAB2IP cells when compared with control Kyse150-vector cells (97 ± 18 vs 206 ± 22 , $P=0.003$), while no obvious difference was observed before IR treatment (0h). Consistently, 36 hours after IR exposure, the colocalized foci number of γ H2AX and 53BP1 was remarkably reduced in DAB2IP-silenced EC109 cells when compared to control EC109-shluc cells (388 ± 36 vs 246 ± 38 , $p=0.038$). However, without IR treatment (0h), no distinct difference was detected in these two group cells. These data indicated that the expression of DAB2IP was associated with DSB repair capability of ESCC cells.

Overexpression of DAB2IP enhances the radiosensitivity of esophageal squamous cell carcinoma cells *in vivo*

To further determine whether DAB2IP has similar impact on ESCC cell response to IR *in vivo*, Kyse150-DAB2IP and control Kyse150-vector cells were inoculated into female BALB/c nude mice. In agreement with our *in vitro* experiments, we found that overexpression of DAB2IP alone did not influence tumorigenicity of ESCC cells, (i.e., both the injected Kyse150-DAB2IP and control Kyse150-vector cells showed a similar efficiency and growth rate of the ESCC xenografts in nude mice)(Figure4A). However, when the mice-bearing tumors received 6Gy of IR, the growth of the Kyse150-DAB2IP tumors was significantly inhibited (from a mean tumor volume of 180mm³ before IR treatment, increasing to 287.00±38.00mm³ at the endpoint of observation). In comparison, the increase in tumor volume of control Kyse150-vector was greater, from a mean tumor volume of 180 mm³ to 423.00±43.00mm³) (*P* <0.01; Figure4A).

The stably overexpressed levels of DAB2IP measured by IHC staining in Kyse150 xenograft tumors are shown inFigure4B. Similar to the results observed in above *in vitro* experiment, the *in vivo* radiation-induced γH2AX foci assay indicated that, 24 hours after receiving 6Gy radiation, the unrepaired DNA damage was substantially increased in Kyse150-DAB2IP xenograft tumor tissues compared to parental control cell line xenograft tumors (Figure4C).

Collectively, the *in vivo* and *in vitro* data demonstrated that DAB2IP plays a crucial role in modulating radiosensitivity of ESCC cells.

DAB2IP regulates ESCC cell radiosensitivity, possibly through enhancing IR-induced activation of ASK1-JNK signaling

Apoptosis is an important mechanism by which IR exerts its therapeutic response and faulty apoptosis is a known mechanism leading to resistance to radiation therapy[21]. In previous literature, DAB2IP has been demonstrated to be involved in several apoptotic pathways, including Ras/Raf/MEK/ERK (MAPK) signaling, PI3K/Akt signaling and ASK1-JNK signaling[22-24]. Therefore, to address which signaling pathways were critically involved in DAB2IP regulating ESCC cells radiosensitivity, we initially performed Western blot to evaluate the phosphorylation levels of AKT, JNK, and ERK, which represent the activated degree of these three signaling pathways, respectively. As shown in Figure5A, in the present of 3Gy IR treatment, stably silencing DAB2IP by lentivirus in EC109 cells obviously increased the protein levels of p-JNK. No changes were observed in p-ERK and p-AKT levels. This result implied that ASK1-JNK signaling pathway might be an important mechanism in DAB2IP regulating ESCC cells radiosensitivity.

DAB2IP facilitates IR-induced dephosphorylation at Ser-966 of ASK1 accompanied by reinforced phosphorylation of JNK

Next, to confirm whether ASK1-JNK pathway was involved in DAB2IP-induced regulation of ESCC cells radiosensitivity, the stably ectopic DAB2IP-overexpressed Kyse150 cells were established and followed by 3Gy X-ray irradiation. The dephosphorylated levels of ASK1 at Ser966 and phosphorylated levels of JNK, both triggered by X-ray irradiation, were determined by Western blot. As illustrated in Figure5B, elevated expression of DAB2IP alone in Kyse150 cells did not alter p-ASK1ser966 and p-JNK levels in the absence

of IR treatment. However, when treated cells with 3Gy IR, ectopic overexpression of DAB2IP remarkably reduced the levels of p-ASK1-ser966, concomitant with a substantially increased levels of p-JNK. These observations were further supported by our results from knockdown experiments. As anticipated, silencing DAB2IP by lentivirus alone in EC109 cells did not affect the protein levels of ASK1 p-Ser966 and p-JNK in the condition without IR. However, in the presence of IR, we observed dramatically increased levels of p-ASK1 Ser966 concurrently with virtual reduction of p-JNK in DAB2IP-depleted EC109 cells when compared with our control EC109-shluc cells (Figure5C).

DAB2IP enhances IR-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3 but not from its other inhibitor, thioredoxin (Trx)

It has been well documented that 14-3-3 is one of the most important inhibitors of ASK1. The dephosphorylation at Ser-966 of human ASK1 and consequent dissociation of 14-3-3 with ASK1 has been thought to be a crucial activation mechanism of ASK1-JNK pathway[25-28]. In addition, it was further reported that DAB2IP could enhance TNF- α -induced ASK1 activation by facilitating dissociation of inhibitor 14-3-3 from ASK1[29]. Thus, we posited that DAB2IP might be capable of intensifying IR-induced ASK1 activation through a similar mechanism. To test this premise, Kyse150 cells were firstly transfected with vector pcDNA3.1 or pcDNA3.1-DAB2IP plasmid, then cells were treated with or without IR, and the association of ASK1 with 14-3-3 was determined by immunoprecipitation with anti-ASK1 followed by Western blot with anti-14-3-3. As expected, the interaction between ASK1 and 14-3-3 was substantially reduced in response to IR treatment, whereas this reduction was reinforced by elevated expression of DAB2IP (Figure5D). Accordingly, the radiation-induced disruptive effect on the ASK1-14-3-3 complex was also observed in EC109 cells, and this disruptive effect was markedly attenuated by knocking down of DAB2IP (Figure5E).

Besides, we also determined whether DAB2IP could affect IR-induced dissociation of ASK1 with Trx, another important negative regulator of ASK1. Intriguingly, our coimmunoprecipitation assay showed that neither knockdown nor overexpression of DAB2IP could impact on IR-induced disruption of ASK1-Trx complex (Figure5D and 5E). This important result has excluded the possibility that DAB2IP regulated IR-induced ASK1 activation by enhancing the dissociation of ASK1 with Trx.

The enhanced activity of DAB2IP on IR-activated JNK signals dependent on the presence of ASK1

In order to further identify whether the sensitizing effect of DAB2IP in response to IR was through ASK1-JNK pathway, Kyse150 cells were firstly stably knocked down ASK1 by lentivirus, and subsequently, the control pcDNA3.1 or pcDNA3.1-DAB2IP plasmid was transfected into these cells to determine whether DAB2IP can still activate JNK signal in the absence of ASK1. As shown in Figure5F, in the presence of IR, the enhanced activity of DAB2IP toward JNK signal was virtually totally prevented in ASK1-depleted Kyse150 cells. These data suggested that the presence of ASK1 was required and might be a predominant mediator for the enhanced activity of DAB2IP toward JNK signal.

Discussion

In our study, we found that decreased expression of DAB2IP in ESCCs correlated positively with ESCC resistance to CRT and was a strong and independent predictor for short disease-specific survival (DSS) of ESCC patients. Subsequently, the crucial role of DAB2IP in regulating ESCC chemoradiosensitivity was confirmed by a series of *in vitro* and *in vivo* experiments. Significantly, our Western blot results showed that p-JNK was reduced in DAB2IP-silenced EC109 cells, suggesting that the ASK1-JNK pathway might be a crucial mechanism involved in DAB2IP modulation of the radiosensitivity of ESCC cells.

Apoptosis signal-regulating kinase 1 (ASK1) was initially identified as a MAP3K, and it selectively activates the c-Jun N-terminal kinase (JNK) and p38 pathways in response to various stimuli[30]. One of the most important activators of ASK1 is oxidative stress. Under normal physiological conditions, ASK1 is maintained in an inactive state through binding to the inhibitory factors thioredoxin (Trx) and 14-3-3 proteins[25,31]. In response to ROS stimulation, Trx is oxidized and dissociated from ASK1. This ROS-induced dissociation of Trx may initiate a conformational change in ASK1, exposing phosphorylated serine residue site (Ser-966 in humans) to a bound serine phosphatase. The phosphorylation of Ser-966 causes the release of 14-3-3 proteins from ASK1, which might finally lead to ASK1 activation[28,32].

To elucidate the detailed mechanism of the ASK1-JNK pathway involvement in DAB2IP regulation of ESCC radiosensitivity, a series of experiments were conducted. Unexpectedly, our Western blot results indicated that ectopic overexpression of DAB2IP alone did not induce the dephosphorylation of Ser-966, and release of 14-3-3 from ASK1, as well as activation of JNK pathways. However, when cells were treated with 3Gy IR, overexpression of DAB2IP obviously enhanced the IR-induced dephosphorylation of Ser-966, leading to increased dissociation of ASK1 from 14-3-3 and the subsequent augmented activation of the JNK pathway. These results suggested that IR might remove the inhibitory factors that are required for the enhanced activation function of DAB2IP on ASK1-JNK signaling.

It is well established that IR can either directly or indirectly generate intracellular reactive oxygen species (ROS), which function as a key intermediates in the radiation mediated induction of apoptotic signaling in tumor cells[33-35]. As we mentioned above, when Trx is oxidized by ROS, it releases from ASK1, permitting ASK1 to be dephosphorylated on Ser-966 by ROS, which, in turn, induces dissociation of ASK1 from its inhibitor protein 14-3-3, ultimately leading to activation of the ASK1-JNK pathway[25,28,31,32]. Accordingly, our immunoprecipitation results showed that IR indeed triggers dissociation of ASK1 from both 14-3-3 and Trx (Figure5D and 5E). This step is necessary for basic activation of ASK1 but not sufficient for intensive ASK1 activation. It is conceivable that IR induces release of 14-3-3 and Trx in a coordinated fashion, permitting DAB2IP to further intensify ASK1 activation. Notably, we observed that only the dissociation of ASK1 from 14-3-3, but not Trx, can be enhanced by DAB2IP. This result excludes the possibility that DAB2IP enhances IR-induced ASK1 activation by facilitating the dissociation of ASK1 from Trx (Figure5D and 5E).

Additionally, one previous important study demonstrated that, with the stimulation of TNF- α , DAB2IP preferentially binds to the locus surrounding the Ser-966-dephosphorylated site of ASK1 and facilitates

dissociation of 14-3-3 through recruitment of the okadaic acid-sensitive phosphatase PP2A to the ASK1 complex, which ultimately leads to the enhanced activation of JNK[29,36]. In agreement with this previous result, our present study also found that DAB2IP could enhance IR-induced dephosphorylation of ASK1-Ser-966, which in turn, facilitates 14-3-3 release from ASK1, ultimately leading to intensive activation of ASK1 (Figure 5B and 5D).

From our collective data, we propose a possible model to illustrate the mechanism of DAB2IP-mediated regulation of radiosensitivity of ESCC cells in Figure 5G. Based on this model, we can easily explain the functional results observed in Figure 3 and Figure 4. That is, without IR treatment, the apoptotic activity of ASK1 was completely repressed by its inhibitors Trx and 14-3-3; thus, without IR treatment, overexpressed DAB2IP per se was incapable of inducing cell apoptosis or suppressing the tumorigenicity of ESCC cells in nude mice (Figure 3B, C and Figure 4A). These results also support the evidence that the release of Trx and 14-3-3 triggered by IR was required for the enhanced killing effects of DAB2IP. Since the mechanisms by which IR kills cells are very complicated and still poorly understood, it is possible that other unknown pathways might also involve in DAB2IP modulation of the radiosensitivity of ESCC cells. Clearly, further studies are needed to confirm this model and elucidate whether other pathways might also contribute to DAB2IP-mediated regulation of the radiosensitivity of ESCC cells.

Conclusion

In summary, our study described, for the first time, the protein expression of DAB2IP in normal human esophageal tissues and in ESCCs. In addition, our results provide a basis for the concept that downregulation of the expression DAB2IP, as detected by IHC, may be a useful tool for predicting CRT resistance and an independent prognostic factor of patients with ESCC treated with definitive CRT. We further demonstrated that the sensitizing effect of DAB2IP in response to IR is through enhanced activation of the ASK1-JNK pathway. These findings might be helpful in clinical practice for selecting potential radioresistant ESCC patients who might require a more intensive follow-up and/or more aggressive treatment.

Declarations

Data accessibility

All data presented within the article and its supplementary information are available upon request from the corresponding author.

Authors' contributors

ZT Tong: Conceptualization, Methodology, Statistical analysis. Y Li: Investigation, Methodology. M Xu: Software, Statistical analysis, Writing - Original Draft. WY Fang: Investigation, Writing - Original Draft. L Sheng: Resources, Data Curation. XC Chen: Investigation JF Xu: Data Curation. L Xiao: Data Curation. SH Pan: Investigation.. HG Pan: Software. HP Chai: Software. TQ Zha: Software. L Zhao: Resources. F

Zhang: Supervision. D Xie: Supervision. All of the authors discussed the results and reviewed the manuscript.

Declaration of competing interests—The authors declare no conflict of interest.

Acknowledgments: We thank Dr. Jiabing Fan (University of California, Los Angeles) for his valuable comments and extensive editing of the manuscript. The authors thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Running Title:DAB2IP modulates chemoradiosensitivity of ESCC

Funding This work was supported by the National Natural Science Foundation of China (81201743), the Postdoctoral Science Foundation Funded Project of Anhui Province (2015B053), and the Doctoral Fund of the Ministry of Education of China (20123420120008).

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians* 2018;68:394-424.
2. Zheng H, Ren W, Pan X, et al. Role of intravoxel incoherent motion mri in early assessment of the response of esophageal squamous cell carcinoma to chemoradiotherapy: A pilot study. *Journal of magnetic resonance imaging : JMRI* 2018;48:349-358.
3. Nakajima M, Kato H. Treatment options for esophageal squamous cell carcinoma. *Expert opinion on pharmacotherapy* 2013;14:1345-54.
4. Chen H, Pong RC, Wang Z, et al. Differential regulation of the human gene dab2ip in normal and malignant prostatic epithelia: Cloning and characterization. *Genomics* 2002;79:573-81.
5. Wang Z, Tseng CP, Pong RC, et al. The mechanism of growth-inhibitory effect of doc-2/dab2 in prostate cancer. Characterization of a novel gtpase-activating protein associated with n-terminal domain of doc-2/dab2. *The Journal of biological chemistry* 2002;277:12622-31.
6. Kong Z, Xie D, Boike T, et al. Downregulation of human dab2ip gene expression in prostate cancer cells results in resistance to ionizing radiation. *Cancer research* 2010;70:2829-39.
7. Yano M, Toyooka S, Tsukuda K, et al. Aberrant promoter methylation of human dab2 interactive protein (hdab2ip) gene in lung cancers. *International journal of cancer* 2005;113:59-66.
8. Qiu GH, Xie H, Wheelhouse N, et al. Differential expression of hdab2ipa and hdab2ipb in normal tissues and promoter methylation of hdab2ipa in hepatocellular carcinoma. *Journal of hepatology* 2007;46:655-63.
9. Zhou J, Luo J, Wu K, et al. Loss of dab2ip in rcc cells enhances their growth and resistance to mtor-targeted therapies. *Oncogene* 2016;35:4663-74.

10. Ji W, Li Y, He Y, et al. Aip1 expression in tumor niche suppresses tumor progression and metastasis. *Cancer research* 2015;75:3492-504.
11. Yu L, Tumati V, Tseng SF, et al. Dab2ip regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-pkcs inhibitor. *Neoplasia* 2012;14:1203-12.
12. Chang R, He H, Mao G, et al. Upregulating dab2ip expression via egr-1 inhibition, a new approach for overcoming fractionated-irradiation-induced cross-tolerance to ionizing radiation and mitomycin c in tumor cells. *International journal of radiation biology* 2017;93:386-393.
13. Cai MY, Tong ZT, Zheng F, et al. Ezh2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. *Gut* 2011;60:967-76.
14. Tong ZT, Cai MY, Wang XG, et al. Ezh2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with hdac1/hdac2 and snail to inhibit e-cadherin. *Oncogene* 2012;31:583-94.
15. He LR, Liu MZ, Li BK, et al. High expression of ezh2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. *International journal of cancer* 2010;127:138-47.
16. Donohoe CL, Phillips AW. Cancer of the esophagus and esophagogastric junction: An 8(th) edition staging primer. *J Thorac Dis* 2017;9:E282-E284.
17. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2004;10:7252-9.
18. Sak A, Stuschke M. Use of gammah2ax and other biomarkers of double-strand breaks during radiotherapy. *Seminars in radiation oncology* 2010;20:223-31.
19. Schultz LB, Chehab NH, Malikzay A, et al. P53 binding protein 1 (53bp1) is an early participant in the cellular response to DNA double-strand breaks. *The Journal of cell biology* 2000;151:1381-90.
20. Burma S, Chen BP, Murphy M, et al. Atm phosphorylates histone h2ax in response to DNA double-strand breaks. *The Journal of biological chemistry* 2001;276:42462-7.
21. Meyn RE, Milas L, Ang KK. The role of apoptosis in radiation oncology. *International journal of radiation biology* 2009;85:107-15.
22. Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating ras and nuclear factor-kappab. *Nature medicine* 2010;16:286-94.
23. Xie D, Gore C, Zhou J, et al. Dab2ip coordinates both pi3k-akt and ask1 pathways for cell survival and apoptosis. *Proceedings of the National Academy of Sciences of the United States of America* 2009;106:19878-83.
24. Zhang H, Zhang R, Luo Y, et al. Aip1/dab2ip, a novel member of the ras-gap family, transduces traf2-induced ask1-jnk activation. *The Journal of biological chemistry* 2004;279:44955-65.

25. Zhang L, Chen J, Fu H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. *Proceedings of the National Academy of Sciences of the United States of America* 1999;96:8511-5.
26. Cockrell LM, Puckett MC, Goldman EH, et al. Dual engagement of 14-3-3 proteins controls signal relay from ask2 to the ask1 signalosome. *Oncogene* 2010;29:822-30.
27. Liu Y, Yin G, Surapisitchat J, et al. Laminar flow inhibits tnfr-induced ask1 activation by preventing dissociation of ask1 from its inhibitor 14-3-3. *The Journal of clinical investigation* 2001;107:917-23.
28. Goldman EH, Chen L, Fu H. Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation. *The Journal of biological chemistry* 2004;279:10442-9.
29. Zhang R, He X, Liu W, et al. Aip1 mediates tnfr-induced ask1 activation by facilitating dissociation of ask1 from its inhibitor 14-3-3. *The Journal of clinical investigation* 2003;111:1933-43.
30. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ask1, a mammalian mapkkk that activates sapk/jnk and p38 signaling pathways. *Science* 1997;275:90-4.
31. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ask) 1. *The EMBO journal* 1998;17:2596-606.
32. Shiizaki S, Naguro I, Ichijo H. Activation mechanisms of ask1 in response to various stresses and its significance in intracellular signaling. *Advances in biological regulation* 2013;53:135-44.
33. Riley PA. Free radicals in biology: Oxidative stress and the effects of ionizing radiation. *International journal of radiation biology* 1994;65:27-33.
34. Wallace SS. Enzymatic processing of radiation-induced free radical damage in DNA. *Radiation research* 1998;150:S60-79.
35. Dayal R, Singh A, Pandey A, et al. Reactive oxygen species as mediator of tumor radiosensitivity. *Journal of cancer research and therapeutics* 2014;10:811-8.
36. Min W, Lin Y, Tang S, et al. Aip1 recruits phosphatase pp2a to ask1 in tumor necrosis factor-induced ask1-jnk activation. *Circulation research* 2008;102:840-8.

Figures

Figure 1

Figure 1

Expression of DAB2IP in ESCC cell lines and tissues and its prognostic significance in ESCC patients. (A) The levels of DAB2IP protein in four ESCC cell lines and normal esophageal mucosa (N1 and N2) examined by Western blot (left); Western blot analysis of DAB2IP protein expression in the 10 representative paired of ESCC (T) and normal esophageal mucosa (N) (right). (B) (a) Representative images showed strong DAB2IP IHC signaling of normal esophageal mucosa. (b) Low DAB2IP expression

was detected in ESCC case #32 (total score=1+1), with 15% (staining percentage score=1) carcinoma cells demonstrated weak staining (staining intensity score=1) of DAB2IP. (c) Moderate DAB2IP expression (total score=6+2) in ESCC case #45, where about 60%-70% (staining percentage score=6) carcinoma cells demonstrated moderate staining (staining intensity score=2) of DAB2IP. (d) High expression (total score=9+3) of DAB2IP was observed in ESCC case #91, with 100% (staining percentage score=9) carcinoma cells demonstrated strong staining (staining intensity score=3) of DAB2IP. (C) X-tile plots of the prognostic marker DAB2IP. X-tile analysis was conducted on patient data from our ESCC cohort. The plot showed the χ^2 log-rank values created when the cohort was divided into two populations. (a) The cut point highlighted by the black/white circle was demonstrated on the histogram. (b) DAB2IP expression was divided at the optimal cut point, as defined by the most significant on the plot. (c, d) Kaplan–Meier survival analysis of DAB2IP expression for OS (n=140, (c)) and DSS (n=112, (d)) in ESCC patients treated with definitive CRT (log-rank test).

Figure 2

Figure 2

The impact of DAB2IP levels on the chemosensitivity of ESCC cells in vitro. (A) Shift of dose-response curves of cisplatin by overexpression or knockdown of DAB2IP was determined by MTS assay. Overexpression of DAB2IP in Kyse150 cells is significantly more sensitive to cisplatin than parental control cells (left). Consistently, knockdown of DAB2IP reduced sensitivity of EC109 cells to cisplatin (right). IC50 values were shown below. (B) Upper panels, Kyse150-DAB2IP and the control Kyse150-

vector cells were treated with cisplatin (IC30), and 24 hours later, the cells were collected and stained with PI and Annexin V. Lower panels, EC109-shLuc and EC109-shDAB2IP cells were incubated with cisplatin (IC30). After 24 hours, Annexin V and PI staining assay was used to determine the percentage of cells undergoing apoptosis. The p-values were calculated by the Student's t test. The bar shows the mean $\pm$ SD of three independent experiments. * $p < 0.05$. (C) Left, 24 hours after cisplatin (IC30) treatment, overexpression of DAB2IP increased the levels of cleaved PARP and cleaved caspase-3 in Kyse150 cells. Right, silencing of DAB2IP decreased cisplatin-induced levels of cleaved PARP and cleaved caspase-3 in EC109 cells.

Figure 3

Figure 3

The expression levels of DAB2IP modulate the radiosensitivity of ESCC cells in vitro. (A) Left, clonogenic survivals of DAB2IP overexpressed cells of Kyse150 cell lines were reduced compared to parental cells after a single dose radiation (0, 2, 4, 6, 8 and 10Gy). Right, knockdown of DAB2IP increased clonogenic survival fraction of EC109. All data were from three independent experiments, and were fitted according to the linear quadratic mode. (B) Left panels, Kyse150-DAB2IP and control Kyse150-vector cells were

treated with or without IR (3Gy), and 48 hours later, the cell apoptotic death events were monitored by Annexin V/PI staining cells. Right panels, EC109 cells, initially infected with DAB2IP-shRNA and Luc-shRNA, were treated with or without IR. After 48 hours, Annexin V/PI staining was used to determine the percentage of cells undergoing apoptosis. All data described are the mean $\pm$ SD of three independent experiments. * $p < 0.05$. All data are reported as mean $\pm$ SD. (C) Forty-eight hours after the cells were treated with IR (3Gy), the cleavages PARP and cleaved caspase-3 were detected in Kyse150-vector/Kyse150-DAB2IP (left) and EC109-shluc/EC109-shDAB2IP (right) cells by Western blot analysis. Experiments were performed three times and a representative result is shown. (D) The levels of DAB2IP affect IR-induced DNA damage in ESCC cells. Kyse150-vector/Kyse150-DAB2IP (upper panels) and EC109-shluc/EC109-shDAB2IP (lower panels) were irradiated with 3Gy and immunostained for 53BP1 (red) and phospho- γ H2AX (green) foci at the indicated time points after radiation. Colocalized foci (yellow) were used as a measure of DSB. Nuclei were counterstained with DAPI (blue). Columns (right) indicate quantification of average numbers of IR-induced colocalized foci per cell (0 or 36 h after IR). A total of 100 cells from three independent experiments were counted for each group. The data represent mean $\pm$ SD. (* $p < 0.05$, p-value was according to Student's t test).

Figure 4

Figure 4

Upregulated expression of DAB2IP enhances the killing-effect of IR on ESCC cell xenografts. (A) Kyse150-DAB2IP or control Kyse150-vectorcells (106) were injected subcutaneously into right flank of athymic nude mice, respectively. When the volume of a transplanted tumor grew to 180mm³, the tumors were received 6Gy dose of IR. The tumor volume of xenografts was measured with calipers every 3 days for a total of 33 days. Overexpressed DAB2IP alone did not affect the growth of the tumors; the mean tumor

volume in the Kyse150-vector and Kyse150-DAB2IP groups was $936\pm68\text{mm}^3$ and $989\pm76\text{mm}^3$, respectively ($n=7$, $p=0.1943$, Student's t test). However, when treated transplanted tumor with 6Gy dose of IR, the mean tumor volume of the Kyse150-vector group was significantly larger than that of the Kyse150-DAB2IP group ($423\pm43\text{ mm}^3$ vs $287\pm38\text{ mm}^3$, $p\leq0.05$). The values represent mean tumor volume $\pm$ SD. (B) Representative images of DAB2IP IHC staining in Kyse150-vector and Kyse150-DAB2IP transplanted tumor tissues. (C) Nude mice xenograft from Kyse150-vector and Kyse150-DAB2IP cells were treated with 6Gy dose of IR, and 0 or 24 hours later, immunofluorescence with antibodies with γ H2AX (green) and 53BP1 (red) was performed. Merged spots (yellow) show colocalization of 53BP1 and γ H2AX foci at DSBs. Experiments were performed three times and a representative result is shown.

Figure 5

Figure 5

The critical role of DAB2IP in modulating IR-induced ASK1-JNK pathway activation. (A) EC109-shluc and EC109-shDAB2IP cells were initially treated with 3Gy dose of IR, and 36 hours later, the indicated protein levels were evaluated by Western blotting. Silencing DAB2IP by lentivirus obviously increased the protein levels of p-JNK. No changes were observed in p-ERK and p-AKT levels. (B) DAB2IP enhanced IR-induced dephosphorylation of ASK1-pSer966 and JNK activation. Kyse150 cells were initially transfected with pcDNA3.1-DAB2IP or vehicle pcDNA3.1 plasmid, followed by treatment with or without IR, and 36 hours later, ASK1-pSer966, and JNK activation were measured by Western blotting. (C) EC109 cells were firstly infected with DAB2IP-shRNA or control luc-shRNA lentivirus, and subsequently received with or without IR. After 36 hours, Western blotting was performed to detect levels of ASK1-pSer966 and p-JNK. Results are representative data of three independent experiments. (D) DAB2IP enhanced IR-induced disruption of ASK1-14-3-3 complex, but not ASK1-Trx complex. Kyse150 cells were initially transfected with pcDNA3.1-DAB2IP or vehicle pcDNA3.1 plasmid, followed by treatment with or without IR, and 36 hours later, cell extracts were firstly immunoprecipitated by anti-ASK1 antibody, and then the precipitate was immunoblotted (IB) with 14-3-3 and Trx antibody. Input was equivalent to 30% of the cell lysate used in the immunoprecipitation. (E) EC109 cells were initially infected with lentivirus carried with DAB2IP-shRNA or luc-shRNA, subsequently received with or without IR. After 36 hours, interaction of ASK1 with endogenous 14-3-3 or Trx was determined by coimmunoprecipitation with primary anti-ASK1 antibody followed by Western blot with 14-3-3 or Trx antibody. The input represents 30% of the cell lysates. Each immunoprecipitation experiment was repeated at least three times and a representative experiment is shown. (F) The enhanced activity of DAB2IP on IR-activated JNK signal was dependent on the presence of ASK1. The Kyse150 cells were firstly infected with ASK1-shRNA or control luc-shRNA lentivirus, and then each group cells were transfected with pcDNA3.1-DAB2IP or vehicle pcDNA3.1 plasmid. All group cells were followed by 3Gy IR treatment, and 36 hours later, JNK activation were evaluated by Western blotting with p-JNK antibody. The representative blots of three independent experiments were shown.

Figure 6

Figure 6

Proposed schematic representation for the molecular mechanism of DAB2IP-induced regulation of radiosensitivity in ESCC cells. In ESCC cells with low or no expression of DAB2IP, IR causes increased levels of intracellular reactive oxygen species (ROS), leading to the dephosphorylation of Ser-966 of ASK1, which consequently triggers dissociation of Trx and 14-3-3 from ASK1, ultimately resulting in a basic activated status of the ASK1-JNK pathway and causing ESCC cells to exhibit low sensitivity/or resistance to radiotherapy. In ESCC cells with normal or overexpression of DAB2IP, the IR-induced ROS stimulates dephosphorylation of Ser-966 of ASK1, thereby releasing of 14-3-3 and Trx from ASK1. This step is necessary but not sufficient for ASK1-enhanced activation. After 14-3-3 and Trx are released from ASK1, DAB2IP preferentially binds to the locus surrounding the Ser966-dephosphorylated site of ASK1, which consequently facilitates dissociation of 14-3-3 from ASK1 and enhances ASK1 kinase activity, ultimately leading to an over-activation of ASK1-JNK signaling and ESCC cells with high sensitivity to radiotherapy.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryTables.docx](#)

- [SupplementaryMaterialsandMethods.docx](#)